At Oxalys Pharmaceuticals, we believe that everyone should be able to access truly effective therapies for brain health. This includes people with rare genetic or age-related neurodegenerative disorders. We aim to develop therapies that are simple to administer, and that can halt, slow, or reverse the course of brain degeneration.
Oxalys was founded by scientists passionate for brain health. Our drug discovery methods and first pipeline therapeutics originated from research at the Massachusetts Institute of Technology (MIT). We work collaboratively with global industry experts and leaders in neurology to develop breakthrough and transformative therapies. Our drug development has been supported by the Michael J Fox Foundation and the National Research Council of Canada.
Our drug discovery technology enables us to seek cures for neurodegenerative disease. We replicate the genetic triggers of neurodegeneration in cultured neuronal cells, and identify compounds that reverse the disease process. This process is rapid and efficient: we are able to test thousands of compounds at a time in a miniaturized format. We offer this drug discovery service to academic and industry partners on a contract basis. Contact us for inquiries.
Chief Executive Officer & Co-founderBio
Chief Scientific Officer & Co-founderBio
The Oxalys team has a shared passion for developing truly effective therapies for neurodegenerative disease. We combine our diverse talents and experience to create breakthrough solutions through constructive collaboration.
Our therapeutics are developed to treat disease progression, not just symptoms. These ‘neuroprotective’ compounds inhibit biological processes that accelerate brain aging. In this way, brain health and function can be retained longer. Our most advanced pipeline therapeutic, OXD4, is highly neuroprotective in preclinical tests, and is applicable to multiple neurodegenerative diseases. We are developing it first for Huntington’s disease, which represents the fastest route to clinical use. Applications to additional disorders, such as Parkinson’s disease, will closely follow.